Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas

• Published in: Cancers 2022-02, Vol.14 (5), p.1186
• Main Authors: Xagoraris, Ioanna, Farrajota Neves da Silva, Pedro, Kokaraki, Georgia, Stathopoulou, Konstantina, Wahlin, Björn, Österborg, Anders, Herold, Nikolas, Ng, Siok-Bian, Medeiros, L Jeffrey, Drakos, Elias, Sander, Birgitta, Rassidakis, George Z
• Format: Article
• Language: English
• Subjects: Anaplastic large-cell lymphoma; Biomarkers; Biopsy; Dendritic cells; Gene expression; Immune response; Immunohistochemistry; Immunomodulation; Immunotherapy; Interferon; Kinases; Lymph nodes; Lymphatic system; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Medical prognosis; Medicin och hälsovetenskap; Mutation; Mycosis; Mycosis fungoides; Natural killer cells; Patients; Proteins; Survival analysis; Therapeutic applications; Therapeutic targets; Transcription; Tumor cell lines; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14051186

The expression patterns of stimulator of interferon genes (STING) were investigated in a cohort of 158 T- and natural killer (NK)-cell and 265 B-cell non-Hodgkin lymphomas (NHLs), as well as in control reactive lymph nodes and tonsils. STING expression was assessed by immunohistochemical methods using diagnostic biopsy specimens obtained prior to treatment. Using an arbitrary 10% cutoff, STING was differentially expressed among T/NK-cell NHLs; positive in 36 out of 38 (95%) cases of ALK+ anaplastic large cell lymphoma (ALCL), 23 out of 37 (62%) ALK-ALCLs, 1 out of 13 (7.7%) angioimmunoblastic T-cell lymphomas, 15 out of 19 (79%) peripheral T-cell lymphomas, not otherwise specified, 20 out of 36 (56%) extranodal NK/T-cell lymphomas of nasal type, 6 out of 7 (86%) T-cell lymphoblastic lymphomas, and 3 out of 4 (75%) mycosis fungoides. STING expression did not correlate with clinicopathological parameters or outcome in these patients with T/NK-cell lymphoma. By contrast, all 265 B-cell NHLs of various types were STING-negative. In addition, STING mRNA levels were very high in 6 out of 7 T-cell NHL cell lines, namely, ALK+ and ALK-ALCL cell lines, and very low or undetectable in 7 B-cell NHL cell lines, suggesting transcriptional downregulation of STING in neoplastic B-cells. At the protein level, using Western blot analysis and immunohistochemistry performed on cell blocks, STING expression was found to be restricted to T-cell NHL cell lines. Taken together, STING expression represents a novel biomarker and therapeutic target in T- and NK-cell lymphomas with direct immunotherapeutic implications since modulators of cGAS-STING activity are already available for clinical use.